The current healthcare environment reshapes the three key factors in market access – value, evidence, and commercial positioning of new treatments. Greater emphasis on patient centricity meets budget cuts. Leading to a sharper focus on demonstrating patient benefit value specific to the treatment situation. At the same time, the focus of new treatments is also being reshaped. To be more personalized in development and delivery.
There cannot be a value-based pricing and reimbursement process without patient- or population-segment centricity. Precise impacts along the patient pathway must be translated into patient-relevant outcomes and then the outcomes monetized along with the costs. Uncertainty must be mitigated. True value-based approaches must go beyond managing access based on budget impact and cost offsets – to enable integrated patient care.
Connect with Ascenian at World EPA Conference on March 21 – 23, 2023, or message firstname.lastname@example.org.
For more content visit tHEORetically Speaking